AUTHOR=Gao Jianfeng , Chen Zhong , Kou Lei , Zhang Hanfang , Yang Yaoguo 

TITLE=The Efficacy of Transcarotid Artery Revascularization With Flow Reversal System Compared to Carotid Endarterectomy: A Systematic Review and Meta-Analysis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.695295

DOI=10.3389/fcvm.2021.695295

ISSN=2297-055X

ABSTRACT=<p><bold>Background:</bold> Carotid artery stenosis has long been a critical cause of stroke and death, and it can seriously affect the life quality. Transcarotid artery revascularization (TCAR) and carotid endarterectomy (CEA) are both feasible therapies for this disease. This systematic review and meta-analysis aim to evaluate if the efficacy of the two approaches is comparable.</p><p><bold>Methods:</bold> Clinical studies up to March 2021 were searched through PubMed, Embase, and Scopus from a computer. The screening process was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Newcastle-Ottawa Scale (NOS) was used for methodological quality assessment of works of literature meeting the inclusion criteria, and Review Manager 5.4 was used for data synthesis. The I<sup>2</sup> statistic was performed to measure the heterogeneity, and M-H/I-V fixed or random model was utilized depending on the I<sup>2</sup> value. The evidence evaluation was accomplished based on grades of recommendation, assessment, development, and evaluation (GRADE) online tool.</p><p><bold>Results:</bold> A total of 14,200 subjects (six comparative studies) were finally included in this pooled study. There is no statistical discrepancy between the two treatments on reducing stroke/death/myocardial infarction (odds ratio [OR] 0.85, 95% CI 0.67–1.07), stroke (OR 1.03, 95% CI 0.77–1.37), or death (OR 1.14, 95% CI 0.67–1.94). Besides, TCAR is associated with a lower incidence of myocardial infarction (<italic>P</italic> = 0.004), cranial nerve injury (<italic>P</italic> &lt; 0.00001), and shorter procedure time (<italic>P</italic> &lt; 0.00001) than CEA among the overall cohort.</p><p><bold>Conclusions:</bold> TCAR is a rapidly developing treatment that reaches a comparable prognosis to CEA and significantly reduces the risk of myocardial infarction under the well-matched condition, which is a dependable choice for patients with carotid stenosis.</p>